Analyst Consensus ?
ConsensusBuy48 ratings
Bullish3062.5%
Neutral1735.4%
Bearish12.1%
FN2 Earnings Intelligence
Biogen Inc. analyst ratings
Biogen Inc. (BIIB) analyst consensus, price targets, and firm-level rating history from FN2 Research.
Analyst 52W Price Targets
$203.91Current
$143Low
$245.56Average
$405High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 30, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Barclays | Equal Weight | Equal Weight | Maintain | Jul 29, 2026 |
| Guggenheim | Buy | Buy | Maintain | Jul 21, 2026 |
| B of A Securities | Neutral | Neutral | Maintain | Jul 21, 2026 |
| Truist Securities | Buy | Hold | Upgrade | Jul 13, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jul 8, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Jul 7, 2026 |
| Needham | Buy | Buy | Maintain | Jun 29, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jun 15, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | May 15, 2026 |
| Citigroup | Neutral | Neutral | Maintain | May 1, 2026 |
| Wedbush | Neutral | Neutral | Maintain | Apr 30, 2026 |
| UBS | Buy | Neutral | Upgrade | Apr 22, 2026 |
| Wells Fargo | Overweight | Equal Weight | Upgrade | Apr 20, 2026 |
| HC Wainwright & Co. | Buy | Buy | Maintain | Apr 2, 2026 |
| Oppenheimer | Outperform | Outperform | Maintain | Apr 1, 2026 |
| Canaccord Genuity | Buy | Buy | Maintain | Apr 1, 2026 |
| HSBC | Reduce | Reduce | Maintain | Mar 17, 2026 |
| Freedom Broker | Hold | Hold | Maintain | Feb 23, 2026 |
| TD Cowen | Buy | Buy | Maintain | Feb 9, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Feb 9, 2026 |
| BMO Capital | Market Perform | Market Perform | Maintain | Feb 9, 2026 |
| Stifel | Buy | Hold | Upgrade | Nov 6, 2025 |
| Bernstein | Market Perform | Market Perform | Maintain | Nov 3, 2025 |
| Baird | Outperform | Outperform | Maintain | May 2, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Apr 23, 2025 |
| Argus Research | Hold | Buy | Downgrade | Apr 4, 2025 |
| Scotiabank | Sector Outperform | Sector Outperform | Maintain | Feb 13, 2025 |
| Jefferies | Hold | Buy | Downgrade | Dec 9, 2024 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Sep 9, 2024 |
| Raymond James | Outperform | Market Perform | Upgrade | Dec 7, 2023 |
| Atlantic Equities | Neutral | Neutral | Maintain | Aug 8, 2023 |
| Cowen & Co. | Outperform | Outperform | Maintain | Feb 16, 2023 |
| SVB Leerink | Outperform | Outperform | Maintain | Oct 26, 2022 |
| William Blair | Outperform | Market Perform | Upgrade | Jun 8, 2021 |
| Credit Suisse | Outperform | Outperform | Maintain | Feb 4, 2021 |
| DZ Bank | Buy | Hold | Upgrade | Nov 10, 2020 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | Apr 23, 2020 |
| Nomura | Buy | Buy | Maintain | Feb 7, 2020 |
| Standpoint Research | Hold | Buy | Downgrade | Nov 1, 2019 |
| Piper Jaffray | Neutral | Overweight | Downgrade | Jun 28, 2019 |
| Stifel Nicolaus | Hold | Buy | Downgrade | Feb 21, 2019 |
| Argus | Hold | Buy | Downgrade | Feb 16, 2018 |
| H.C. Wainwright | Buy | Buy | Maintain | Jan 26, 2018 |
| Bank of America | Buy | Buy | Maintain | Oct 18, 2017 |
| Leerink Swann | Market Perform | Outperform | Downgrade | Mar 16, 2017 |
| PiperJaffray | Overweight | Neutral | Upgrade | Nov 7, 2016 |
| Deutsche Bank | Buy | Buy | Maintain | Jul 24, 2014 |
| FBR Capital | Outperform | Outperform | Maintain | Oct 2, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $203.91. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Oppenheimer | Jay Olson | $300 | $209.23 | +47.1% | Jul 29, 2026 |
| Guggenheim | Yatin Suneja | $280 | $203.02 | +37.3% | Jul 21, 2026 |
| Wedbush | Analyst unavailable | $201 | $202.04 | -1.4% | Jul 13, 2026 |
| Truist Financial | Analyst unavailable | $235 | $199.15 | +15.2% | Jul 13, 2026 |
| Morgan Stanley | Terence Flynn | $222 | $205.7 | +8.9% | Jul 8, 2026 |
| RBC Capital | Analyst unavailable | $242 | $208.46 | +18.7% | Jul 7, 2026 |
| HSBC | Morten Herholdt | $157 | $213.26 | -23.0% | Jul 6, 2026 |
| Morgan Stanley | Analyst unavailable | $224 | $198.67 | +9.9% | Jun 18, 2026 |
| Mizuho Securities | Salim Syed | $221 | $200.05 | +8.4% | Jun 15, 2026 |
| Needham | Analyst unavailable | $255 | $195.34 | +25.1% | Jun 8, 2026 |
| RBC Capital | Brian Abrahams | $227 | $193.08 | +11.3% | May 27, 2026 |
| Piper Sandler | Analyst unavailable | $225 | $191.37 | +10.3% | May 15, 2026 |
| Morgan Stanley | Analyst unavailable | $206 | $188.76 | +1.0% | Apr 30, 2026 |
| RBC Capital | Brian Abrahams | $222 | $190.78 | +8.9% | Apr 30, 2026 |
| Wedbush | Analyst unavailable | $196 | $194.38 | -3.9% | Apr 30, 2026 |
| Guggenheim | Analyst unavailable | $260 | $194.38 | +27.5% | Apr 30, 2026 |
| Wells Fargo | Mohit Bansal | $250 | $177.35 | +22.6% | Apr 20, 2026 |
| Piper Sandler | Analyst unavailable | $214 | $176.36 | +4.9% | Apr 14, 2026 |
| Morgan Stanley | Analyst unavailable | $200 | $173.48 | -1.9% | Apr 10, 2026 |
| Barclays | Emily Field | $185 | $192.08 | -9.3% | Feb 19, 2026 |
| Mizuho Securities | Analyst unavailable | $236 | $188.99 | +15.7% | Feb 11, 2026 |
| Wedbush | Laura Chico | $187 | $192.72 | -8.3% | Feb 10, 2026 |
| Wolfe Research | Analyst unavailable | $231 | $196 | +13.3% | Feb 9, 2026 |
| RBC Capital | Analyst unavailable | $233 | $195.93 | +14.3% | Feb 9, 2026 |
| Wolfe Research | Analyst unavailable | $215 | $195.45 | +5.4% | Feb 9, 2026 |
| Truist Financial | Danielle Brill | $193 | $201.18 | -5.4% | Feb 9, 2026 |
| Canaccord Genuity | Analyst unavailable | $230 | $201.18 | +12.8% | Feb 9, 2026 |
| Piper Sandler | Analyst unavailable | $177 | $201.18 | -13.2% | Feb 9, 2026 |
| Guggenheim | Yatin Suneja | $246 | $201.18 | +20.6% | Feb 9, 2026 |
| Tudor Pickering | William Pickering | $201 | $201.18 | -1.4% | Feb 9, 2026 |
| H.C. Wainwright | Andrew Fein | $228 | $201.18 | +11.8% | Feb 9, 2026 |
| Wells Fargo | Analyst unavailable | $200 | $201.18 | -1.9% | Feb 8, 2026 |
| Morgan Stanley | Terence Flynn | $190 | $201.18 | -6.8% | Feb 8, 2026 |
| BMO Capital | Evan Seigerman | $196 | $201.18 | -3.9% | Feb 6, 2026 |
| Bernstein | Analyst unavailable | $191 | $179.09 | -6.3% | Feb 3, 2026 |
| Oppenheimer | Jay Olson | $225 | $176.18 | +10.3% | Jan 30, 2026 |
| Truist Financial | Analyst unavailable | $190 | $186.19 | -6.8% | Jan 8, 2026 |
| Goldman Sachs | Salveen Richter | $225 | $186.91 | +10.3% | Jan 8, 2026 |
| UBS | Analyst unavailable | $185 | $182.61 | -9.3% | Jan 6, 2026 |
| Morgan Stanley | Terence Flynn | $156 | $173.9 | -23.5% | Dec 12, 2025 |
| HSBC | Analyst unavailable | $143 | $175.8 | -29.9% | Dec 10, 2025 |
| Piper Sandler | Analyst unavailable | $157 | $168.18 | -23.0% | Nov 21, 2025 |
| Tudor Pickering | William Pickering | $157 | $153.64 | -23.0% | Nov 3, 2025 |
| Bernstein | Analyst unavailable | $157 | $154.27 | -23.0% | Nov 3, 2025 |
| Robert W. Baird | Analyst unavailable | $250 | $151.6 | +22.6% | Oct 31, 2025 |
| Morgan Stanley | Analyst unavailable | $149 | $150 | -26.9% | Oct 10, 2025 |
| Jefferies | Andrew Tsai | $190 | $137.67 | -6.8% | Sep 25, 2025 |
| RBC Capital | Brian Abrahams | $213 | $127.31 | +4.5% | Jun 25, 2025 |
| H.C. Wainwright | Andrew Fein | $187 | $122.41 | -8.3% | May 5, 2025 |
| Oppenheimer | Jay Olson | $205 | $123.53 | +0.5% | May 2, 2025 |
| HSBC | Analyst unavailable | $118 | $119.12 | -42.1% | Apr 28, 2025 |
| Canaccord Genuity | Sumant Kulkarni | $265 | $138.06 | +30.0% | Feb 13, 2025 |
| Needham | Ami Fadia | $270 | $133.43 | +32.4% | Feb 12, 2025 |
| Jefferies | Michael Yee | $180 | $157.78 | -11.7% | Dec 9, 2024 |
| Robert W. Baird | Brian Skorney | $300 | $162.83 | +47.1% | Nov 15, 2024 |
| Oppenheimer | Jay Olson | $255 | $181.18 | +25.1% | Oct 31, 2024 |
| Morgan Stanley | Terence Flynn | $204 | $181.18 | +0.0% | Oct 31, 2024 |
| Raymond James | Christopher Raymond | $315 | $181.18 | +54.5% | Oct 30, 2024 |
| Goldman Sachs | Salveen Richter | $290 | $181.18 | +42.2% | Oct 30, 2024 |
| BMO Capital | Evan Seigerman | $230 | $188.16 | +12.8% | Oct 17, 2024 |
| UBS | Ashwani Verma | $202 | $188.74 | -0.9% | Oct 3, 2024 |
| Wedbush | Laura Chico | $205 | $199.36 | +0.5% | Sep 23, 2024 |
| Robert W. Baird | Brian Skorney | $294 | $212.7 | +44.2% | Jul 29, 2024 |
| Goldman Sachs | Salveen Richter | $342 | $211.17 | +67.7% | Jul 26, 2024 |
| Piper Sandler | Christopher Raymond | $307 | $211.17 | +50.6% | Jul 26, 2024 |
| RBC Capital | Brian Abrahams | $282 | $214.16 | +38.3% | Jul 26, 2024 |
| Piper Sandler | Christopher Raymond | $313 | $236.8 | +53.5% | Jul 12, 2024 |
| Morgan Stanley | Terence Flynn | $311 | $232.75 | +52.5% | Jul 11, 2024 |
| Scotiabank | George Farmer | $275 | $230.28 | +34.9% | Jun 12, 2024 |
| BMO Capital | Evan David Seigerman | $260 | $220 | +27.5% | May 23, 2024 |
| Stifel Nicolaus | Paul Matteis | $275 | $225.21 | +34.9% | May 22, 2024 |
| Raymond James | Christopher Raymond | $335 | $225.21 | +64.3% | May 22, 2024 |
| Morgan Stanley | Matthew Harrison | $331 | $224.48 | +62.3% | May 22, 2024 |
| Wedbush | Laura Chico | $215 | $204.65 | +5.4% | Apr 25, 2024 |
| H.C. Wainwright | Andrew Fein | $300 | $201.99 | +47.1% | Apr 25, 2024 |
| RBC Capital | Brian Abrahams | $317 | $201.99 | +55.5% | Apr 25, 2024 |
| Oppenheimer | Jay Olson | $270 | $190.52 | +32.4% | Apr 19, 2024 |
| Barclays | Carter Gould | $215 | $206.38 | +5.4% | Apr 3, 2024 |
| Wedbush | Laura Chico | $269 | $271.23 | +31.9% | Aug 7, 2023 |
| Guggenheim | Yatin Suneja | $350 | $311.11 | +71.6% | May 1, 2023 |
| Atlantic Equities | Analyst unavailable | $295 | $305.17 | +44.7% | Dec 1, 2022 |
| Jefferies | Analyst unavailable | $350 | $308.44 | +71.6% | Nov 30, 2022 |
| Wedbush | Analyst unavailable | $247 | $302.84 | +21.1% | Nov 30, 2022 |
| Barclays | Analyst unavailable | $313 | $291.41 | +53.5% | Nov 30, 2022 |
| Truist Financial | Analyst unavailable | $350 | $301.86 | +71.6% | Nov 15, 2022 |
| Guggenheim | Analyst unavailable | $270 | $286.86 | +32.4% | Nov 11, 2022 |
| J.P. Morgan | Analyst unavailable | $275 | $264.28 | +34.9% | Sep 30, 2022 |
| Atlantic Equities | Steve Chesney | $200 | $271.16 | -1.9% | Sep 28, 2022 |
| Wedbush | Analyst unavailable | $217 | $277.58 | +6.4% | Sep 28, 2022 |
| Wells Fargo | Analyst unavailable | $350 | $270.28 | +71.6% | Sep 28, 2022 |
| RBC Capital | Analyst unavailable | $321 | $275.88 | +57.4% | Sep 28, 2022 |
| Piper Sandler | Analyst unavailable | $280 | $197.79 | +37.3% | Sep 28, 2022 |
| Mizuho Securities | Salim Syed | $270 | $197.79 | +32.4% | Sep 28, 2022 |
| Needham | Ami Fadia | $250 | $197.79 | +22.6% | Sep 28, 2022 |
| Robert W. Baird | Brian Skorney | $340 | $197.79 | +66.7% | Sep 28, 2022 |
| Truist Financial | Analyst unavailable | $265 | $195.92 | +30.0% | Sep 22, 2022 |
| Stifel Nicolaus | Analyst unavailable | $223 | $215.38 | +9.4% | Sep 12, 2022 |
| Cowen & Co. | Analyst unavailable | $270 | $214.1 | +32.4% | Jul 21, 2022 |
| Truist Financial | Analyst unavailable | $270 | $213.15 | +32.4% | Jul 21, 2022 |
| Barclays | Analyst unavailable | $200 | $212.95 | -1.9% | Jul 21, 2022 |
| Oppenheimer | Analyst unavailable | $230 | $216.68 | +12.8% | Jul 18, 2022 |
| Barclays | Analyst unavailable | $210 | $205.7 | +3.0% | May 4, 2022 |
| Leerink Partners | Analyst unavailable | $270 | $221.36 | +32.4% | Apr 21, 2022 |
| Wells Fargo | Mohit Bansal | $265 | $212.55 | +30.0% | Apr 18, 2022 |
| Barclays | Carter Gould | $219 | $212.55 | +7.4% | Apr 16, 2022 |
| Needham | Ami Fadia | $262 | $210.62 | +28.5% | Apr 11, 2022 |
| Wedbush | Laura Chico | $185 | $214.75 | -9.3% | Apr 9, 2022 |
| Jefferies | Michael Yee | $300 | $211.64 | +47.1% | Apr 7, 2022 |
| Robert W. Baird | Brian Skorney | $224 | $211.64 | +9.9% | Apr 7, 2022 |
| Piper Sandler | Christopher Raymond | $200 | $211.64 | -1.9% | Apr 7, 2022 |
| RBC Capital | Brian Abrahams | $244 | $207.61 | +19.7% | Apr 5, 2022 |
| Bank of America Securities | Geoff Meacham | $225 | $211.68 | +10.3% | Mar 28, 2022 |
| BMO Capital | Evan Seigerman | $238 | $197.36 | +16.7% | Mar 15, 2022 |
| Canaccord Genuity | Sumant Kulkarni | $285 | $211.01 | +39.8% | Feb 28, 2022 |
| Guggenheim | Yatin Suneja | $200 | $209.81 | -1.9% | Feb 22, 2022 |
| Truist Financial | Robyn Karnauskas | $320 | $214.55 | +56.9% | Feb 16, 2022 |
| Needham | Ami Fadia | $290 | $214.59 | +42.2% | Feb 13, 2022 |
| Mizuho Securities | Salim Syed | $207 | $221.3 | +1.5% | Feb 7, 2022 |
| Morgan Stanley | Matthew Harrison | $330 | $221.53 | +61.8% | Feb 4, 2022 |
| Barclays | Carter Gould | $235 | $221.53 | +15.2% | Feb 4, 2022 |
| Wolfe Research | Tim Anderson | $217 | $221.53 | +6.4% | Feb 4, 2022 |
| Wells Fargo | Mohit Bansal | $235 | $221.53 | +15.2% | Feb 4, 2022 |
| Cowen & Co. | Phil Nadeau | $285 | $221.53 | +39.8% | Feb 4, 2022 |
| J.P. Morgan | Cory Kasimov | $236 | $220.17 | +15.7% | Feb 3, 2022 |
| Needham | Ami Fadia | $292 | $225.21 | +43.2% | Jan 30, 2022 |
| Jefferies | Michael Yee | $325 | $239.3 | +59.4% | Jan 16, 2022 |
| Cantor Fitzgerald | Alethia Young | $209 | $225.34 | +2.5% | Jan 12, 2022 |
| Bernstein | Aaron Gal | $400 | $244.14 | +96.2% | Jan 3, 2022 |
| Goldman Sachs | Salveen Richter | $271 | $224.11 | +32.9% | Dec 6, 2021 |
| UBS | Colin Bristow | $405 | $266.57 | +98.6% | Oct 20, 2021 |
| Atlantic Equities | Steve Chesney | $415 | $395.37 | +103.5% | Jun 8, 2021 |
Track every rating change on BIIB the moment it posts. Free to start.
Start free